The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion

Sophie Park 1 · Charikleia Kelaidi 2 · Mathieu Meunier 1 · Nicole Casadevall 3 · Aaron T. Gerds 4 · Uwe Platzbecker 5

Received: 16 May 2019 / Accepted: 11 September 2019 / Published online: 25 October 2019 © The Author(s) 2019, corrected publication 2019

Abstract

Myelodysplastic syndromes (MDS) are hematopoietic stem cell malignancies associated with an erythroid maturation defect, resulting in anemia. Treatments for MDS include erythropoiesis-stimulating agents (ESAs). The identification of prognostic markers is important to help predict response and improve outcomes. Various scoring systems have been developed to help predict response to ESAs. Despite limitations in its assessment, serum erythropoietin (sEPO) level is an important predictor of hematologic response to ESAs in patients with lower-risk MDS. Numerous studies have reported significantly lower sEPO levels among responders versus non-responders. Furthermore, treatment response is significantly more likely among those with sEPO levels below versus those above various cutoffs. Other prognostic indicators for response to ESAs include lower transfusion requirement, fewer bone marrow blasts, higher hemoglobin, lower serum ferritin, lower-risk MDS, and more normal cytogenetics. Studies of other MDS therapies (e.g., lenalidomide and luspatercept) have also reported that lower sEPO levels are indicative of hematologic response. In addition, lower sEPO levels (up to 500 IU/L) have been included in treatment algorithms for patients with lower-risk MDS to define whether ESAs are indicated. Lower sEPO levels are predictive of hematologic response—particularly to ESAs. Further, clinical trials should use sEPO thresholds to ensure more homogeneous cohorts.

Keywords Erythropoietin · Myelodysplastic syndromes · Prognosis · Erythropoiesis-stimulating agents · Hematologic response

Introduction

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell malignancies that are characterized by an erythroid maturation defect, resulting in anemia, and can develop into acute myeloid leukemia (AML) [1, 2]. World Health Organization (WHO) MDS classifications from 2002 included refractory anemia (RA), refractory anemia with ring sideroblasts (RARS), refractory cytopenia with multilineage dysplasia (RCMD), RCMD and ring sideroblasts (RCMD-RS), refractory anemia with excess blasts (RAEB), and MDS associated with isolated del(5q) [3]. The most recent 2016 WHO MDS classifications are slightly different and include MDS with single lineage or multilineage dysplasia, MDS with ring sideroblasts and single or multilineage dysplasia, MDS with excess blasts, and MDS with isolated del(5q) [4].

The prognosis of patients with MDS, which is highly variable, can be assessed using various prognostic scoring systems. The earliest of these—the 1997 International Prognostic Scoring System (IPSS)—was largely based on the percentage of bone marrow blasts and karyotype [5]. The WHO classification–based Prognostic Scoring System (WPSS), which was introduced in 2007 [6], was largely based on the 2002 WHO MDS classifications [3] and karyotype. The recently revised 2012 IPSS (IPSS-R) [7] provides improved risk stratification over the original IPSS by incorporating more detailed cytogenetic subgroups and different thresholds for
blastic percentage and degree of cytopenias. These systems can all be used to categorize patients’ risks (e.g., low, intermediate, or high) in terms of survival and leukemic evolution.

A key first-line treatment option for many patients with symptomatic anemia associated with lower-risk MDS is erythropoiesis-stimulating agents (ESAs) (e.g., epoetin alpha or darbepoetin alpha), which may also be combined with granulocyte colony–stimulating factor (G-CSF) [8]. However, these are only recommended for patients with serum erythropoietin (sEPO) levels up to 500 IU/L [8]. In this review, we discuss the issues surrounding sEPO assessment and examine the available evidence for its prognostic value—primarily for response to ESAs—among patients with lower-risk MDS. We also discuss other prognostic markers for response to ESAs, and the inclusion of sEPO and other markers in various ESA response prediction scoring systems.

**Erythropoietin characterization**

The concept of a hormone that regulates red blood cell (RBC) production was proposed in 1906 [9, 10] and, in 1948 [11], it was termed “erythropoietin” (EPO) [12]. EPO is mainly (90%) synthesized in peritubular cells in the kidney [13–15], with the remainder being produced in the liver [16]. Human EPO was first purified in 1977 [17] and the human EPO gene was cloned in 1985 [18, 19]. Recombinant human EPO (rhEPO) was shown to be comparable to natural EPO in 1986 [20] and, in 1987, synthetic EPO was first used to treat anemia associated with end-stage renal disease [21].

It is now well known that RBC production is regulated by EPO [12], which it does by binding to EPO receptors that are mainly expressed on immature erythroid cells [22, 23], thus stimulating their transformation into mature erythrocytes.

**sEPO assessment**

Although sEPO assessment can be difficult due to its very low concentration in plasma (normally around 50 ng/L) [12], the first reliable bioassay was developed in 1955 [12, 24]. Originally, 1 unit of EPO was defined as the dose that gave the same erythropoiesis-stimulating response as 5-μmol cobaltous chloride [12]. In 1961, EPO standard A was produced (from sheep plasma), but this was quickly replaced by EPO standard B (from human urine) [25]. The international unit (IU) for EPO was then defined as the activity contained in 1.48 mg of EPO standard B [25]. The second international reference preparation of EPO was established in 1972 [26] and, in 1992, a purified recombinant deoxyribonucleic acid–derived human EPO was introduced [27].

A reliable radioimmunoassay for EPO was first developed in 1979 [12, 28] and enzyme-linked immunoassay kits are now used to measure EPO levels. Although currently available kits have good sensitivity (<1 IU/L), their range generally only extends up to 100 IU/L [29–32] or 200 IU/L [33]. Although this is suitable for the general population, in whom sEPO levels are approximately 8 IU/L [34], they may not be able to accurately measure sEPO levels in MDS patients with symptomatic anemia, who can have highly elevated sEPO levels (>10,000 IU/L [35]). Another potential complication when measuring sEPO levels is that they can vary throughout the day, although this is more significant in healthy individuals than in patients with MDS [36]. Accurate measurement of sEPO levels may also be complicated by the range of kits available, as there is likely some heterogeneity between them.

**Prognostic factors for response to ESAs in patients with MDS**

In general, factors that can be used to predict response to treatments can be used to tailor treatments more efficiently and, hence, improve outcomes. Many studies have examined factors that are prognostic for response to ESAs (with or without G-CSF) among patients with lower-risk MDS, and these are discussed below. Of note, response definitions were generally based on International Working Group (IWG) hematologic improvement criteria from 2000 [37] or 2006 [38], but this varied by study (as detailed in Table 1 [39–62] and Fig. 1 [39–52, 54, 56, 57, 59–65]).

**sEPO levels and response to ESAs**

Multiple studies have reported correlations between sEPO levels and response to ESAs with or without G-CSF among predominantly lower-risk MDS patients (Table 1) [39–62]. Nearly all the studies listed in Table 1 reported response rates to ESAs with or without G-CSF among patients with sEPO levels below versus above various cutoff levels. The most commonly reported sEPO cutoff was 100 IU/L, for which reported response rates were 50–93% for patients with sEPO < 100 IU/L versus 12–58% for patients with sEPO > 100 IU/L. Using a sEPO cutoff of 200 IU/L, 45–82% of patients with sEPO below the cutoff versus 5–53% of patients with higher sEPO levels responded; for a cutoff of 500 IU/L, 48–55% versus 10–16% responded, respectively. Most response comparisons by above versus below sEPO cutoff were significant.

Among studies that reported mean or median sEPO levels among responders versus non-responders, all reported lower sEPO levels among responders, although the actual values varied widely between studies (Table 1). The sEPO differences were significant in all but two studies: significance was not reported in one study [49] and one study only included 24 patients [49].
| Reference               | Treatment                          | n  | Response definition                                                                 | sEPO responders vs non-responders, IU/L | sEPO cutoffs, IU/L | Response by sEPO, % |
|------------------------|------------------------------------|----|-------------------------------------------------------------------------------------|-----------------------------------------|--------------------|---------------------|
| Hellstrom-Lindberg     | EPO + G-CSF                         | 98 | Hb ≥ 115 g/L or Hb † ≥ 15 g/L or 100% reduction in transfusion need and stable Hb for ≥ 6 weeks | 118 (range 6–1144) vs 741 (range 8–5921) (P < 0.001) | ≤ 100 vs > 100 | 64 vs 26 (P < 0.001) |
|                        |                                    |    |                                                                                     |                                         | ≤ 500 vs > 500 | 55 vs 10 (P < 0.001) |
|                        |                                    |    |                                                                                     |                                         | < 100 vs > 100 | 100 vs 50 (P = 0.004) |
|                        |                                    |    |                                                                                     |                                         | < 200 vs > 200 | 200 vs 100 (P = 0.005) |
|                        |                                    |    |                                                                                     |                                         | 200–500 vs > 200 | 100 vs 200 (P = 0.006) |
|                        |                                    |    |                                                                                     |                                         | NR | 200 vs 50 (P = 0.008) |

**Table 1** sEPO levels predictive of hematologic response to ESAs in patients with MDS (mainly lower-risk)
| Reference  | Treatment       | n   | Response definition | sEPO responders vs non-responders, IU/L<sup>a</sup> | sEPO cutoffs, IU/L | Response by sEPO, % |
|------------|-----------------|-----|---------------------|-------------------------------------------------|-------------------|-------------------|
| Santini [56]| ESA             | 456 | NR                  | ≤ 100 vs > 100                                  | 75 vs 45 (P < 0.0002) |
|            |                 |     |                     | ≤ 200 vs > 200                                  | 75 vs 31 (P < 0.0001) |
| Molteni [57]| EPO             | 58  | NR                  | ≤ 80 vs > 80                                    | OR = 0.10; 95% CI, 0.03–0.35 (P<sub>uni</sub> < 0.0005) |
|            |                 |     |                     | ≤ 100 vs > 100                                  | OR = 0.16; 95% CI, 0.05–0.54 (P<sub>multi</sub> = 0.003) |
| Jang [58]  | Darbepoietin alpha | 50  | NR                  | < 100 vs ≥ 100                                  | 93 vs 44 (P = NR) |
|            |                 |     |                     | < 200 vs ≥ 200                                  | 82 vs 39 (P = NR) |
|            |                 |     |                     | < 300 vs ≥ 300                                  | 62 vs 50 (P = NR) |
| Kosmider [59]| ESA             | 79  | NR                  | ≤ 100 vs > 100                                  | 76 vs 39 (P<sub>uni</sub> = 0.002; P<sub>multi</sub> = 0.04) |
| Buckstein [60]| ESA ± G-CSF     | 996 | NR                  | ≤ 100 vs > 100                                  | OR = 2.3 (P = 0.001) |
| Houston [61]| ESA ± G-CSF     | 208 | NR                  | ≤ 100 vs > 100                                  | OR<sub>uni</sub> = 8.3 (P<sub>uni</sub> < 0.0001); OR<sub>multi</sub> = 8.7 (P<sub>multi</sub> < 0.0001) |
|            |                 |     |                     | < 200 vs ≥ 200                                  | OR<sub>uni</sub> = 4.9 (P<sub>uni</sub> = 0.007) |
| Park [62]  | ESA ± G-CSF     | 1698| NR                  | 60 (IQR 21–75) vs 183 (IQR 38–323) vs 245 (IQR 49–260) (P < 0.001)<sup>d</sup> | NR                 | NR                |

CI confidence interval, EPO erythropoietin, ESA erythropoiesis-stimulating agent, G-CSF granulocyte colony–stimulating factor, Hb hemoglobin, IQR interquartile range, IU international unit, IWG International Working Group, MDS myelodysplastic syndromes, NR not reported, NS not significant, OR odds ratio, OR<sub>multi</sub> odds ratio by multivariable analysis, OR<sub>uni</sub> odds ratio by univariate analysis, P<sub>multi</sub> P value by multivariable analysis, P<sub>uni</sub> P value by univariate analysis, RBC red blood cell, SD standard deviation, sEPO serum erythropoietin

<sup>a</sup> Values are mean ± SD or median (range or IQR) for responders versus non-responders

<sup>b</sup> IWG 2000 response criteria: for patients with pretreatment Hb < 110 g/L, ≥ 10 g/L increase in Hb; for RBC transfusion-dependent patients, 50% decrease in transfusion requirements. Responses have to last ≥ 2 months [38]

<sup>c</sup> IWG 2006 response criteria: for patients with pretreatment Hb < 110 g/L, ≥ 15 g/L increase in Hb; reduction of ≥ 4 RBC transfusions/8 weeks versus pretreatment 8 weeks (only RBC transfusions for a Hb ≤ 9.0 g/dL). Responses have to last ≥ 8 weeks [39]

<sup>d</sup>In these studies, sEPO levels were reported for patients who responded and did not relapse versus those who responded and relapsed versus those with primary resistance to ESAs
Two studies classified patients as having primary resistance to ESAs, relapsing after an initial response, or continuing to respond [55, 62]. Median sEPO levels in these three groups decreased significantly from resistant to relapsing to responding (Table 1) [55, 62].

Of note, among studies that reported ranges of sEPO levels among responders and non-responders, patients with an sEPO level as high as 1144 IU/L responded, while those with an sEPO level as low as 8 IU/L did not respond (Table 1), suggesting that sEPO levels cannot be guaranteed to predict response. Hence, additional prognostic indicators are needed.

**Other factors predictive of response to ESAs**

A wide range of other markers have been correlated with improved hematologic response to ESAs with or without sEPO levels.
G-CSF among patients with lower-risk MDS (Fig. 1) [39–52, 54, 56, 57, 59–65]. The most commonly reported non-sEPO markers for improved response are lower transfusion requirement and higher hemoglobin level. Other commonly cited markers include fewer bone marrow blasts (lower percentage or RA/RARS rather than RAEB), lower serum ferritin level, lower-risk MDS using various prognostic schemes (e.g., IPSS, WPSS, IPSS-R), and more normal cytogenetics (e.g., lower-risk IPSS-R karyotypes). There have also been reports that lower tumor necrosis factor alpha level, being ESA-naïve, and shorter time to ESA onset are associated with improved response. A recent meta-analysis of darbepoetin alpha in MDS [66] has similarly reported that being ESA-naïve and having higher baseline hemoglobin level, higher dose, transfusion independence, and low-risk IPSS—along with sEPO level below 100 IU/L—are all linked with improved response rates.

It should be noted that many of the abovementioned factors that have been correlated with improved response to ESAs have also been correlated with improved prognosis [5–7]. It is therefore possible that patients with less aggressive disease are more likely to respond to ESAs, so these markers (including sEPO) may actually be predictors of disease severity rather than merely response to ESAs [67].

One study has examined the effect of somatic mutations on erythroid response [59]. In univariate analysis, having more than two mutations reduced the likelihood of response (odds ratio [OR], 0.29; 95% confidence interval [CI], 0.11–0.78; \( P = 0.01 \)) compared with fewer mutations, but this was no longer significant in multivariate analysis. Higher numbers of mutations were, however, correlated with worse overall survival (hazard ratio [HR], 2.53; 95% CI, 1.00–7.20; \( P = 0.05 \)), which suggests that alternative treatments may be required in such patients.

**Scoring systems predictive of hematologic response to ESAs among patients with MDS**

Based on the most influential predictive factors discussed above, various groups have proposed scoring systems to predict hematologic response to ESAs with or without G-CSF among patients with MDS (Table 2) [39, 56, 60, 61]. These all include sEPO levels, although the cutoffs and scores vary between systems. The earliest system additionally included only transfusion need [39]. Later systems [56, 60, 61] included either IPSS-R or IPSS risk levels. Response rates for the most favorable scores are 74–85%, falling to 7–23% for the least favorable scores (Table 2).

Various groups have corroborated the Nordic score [39] is predictive of response to ESAs. Remacha et al. [63] reported response rates to rhEPO with or without G-CSF of 78% versus 15% for scores of > 1 versus ± 1 (\( P_{\text{uni}} = 0.0001 \); risk ratio [RR], 11.6; 95% CI, 2.5–53; \( P_{\text{multi}} = 0.0016 \)) among 32 patients [63]. Hellstrom-Lindberg et al. [42] later validated their own score in 53 patients, showing that 61% versus 14% of those with scores of > 1 versus ± 1 responded (\( P = 0.001 \)). Similarly, Molteni et al. [57] reported that 64% versus 33% of those with scores of > 1 versus ± 1 responded (\( P = 0.05 \)). However, they also reported that 79% versus 33% of patients with scores of 4 versus 3 responded (\( P = 0.004 \)), showing that those with a score of 3 had the same response rate as those with a score of ± 1.

Houston et al. [61], who designed the myelodysplastic syndromes-Canada ESA (MDS-CAN ESA) score, also tested the Nordic [39] and European [56] scores. Using the Nordic score, they found that 57% versus 31% of patients with scores of > 1 versus ± 1 responded (\( P = 0.01 \)) [61]. They reported a non-significant declining trend of response rate to ESAs (67% vs 58% vs 52% vs 40% vs 13%) with increasing European scores. However, the lack of significance was likely due to a lack of power as all the required variables (ferritin, sEPO, and IPSS-R) were only available in 92 patients. Buckstein et al. [60], who designed the Italy-Canada (ITACA) score, also tested the Nordic, European, and MDS-CAN ESA scores (Table 2), but in much larger numbers of patients (\( n = 846, 524, \) and 702, respectively). They reported response rates of 68–78% for the best categories, falling to 20–38% for the worst categories for these three scores, suggesting that all of them could be very beneficial in predicting response to ESAs.

**Inclusion of sEPO assessments in MDS treatment guidelines**

The importance of the predictive value of sEPO for response to ESAs is corroborated by its inclusion as a deciding factor for treatment in various MDS guidelines. For example, for patients with lower-risk MDS and symptomatic anemia, the current National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN guidelines®) for Myelodysplastic Syndromes depend on the presence/absence of the del(5q) cytogenetic abnormality and sEPO level [8]. For patients with del(5q), lenalidomide is indicated; for patients without del(5q), ESAs (epoetin alpha or darbepoetin alpha) are only recommended for those patients with sEPO levels up to 500 IU/L; for patients without del(5q) and sEPO levels above 500 IU/L, biologic response modifiers, hypomethylating agents, or clinical trials are indicated [8]. Similarly, the American Society of Hematology [68] only recommends ESAs for patients with lower-risk MDS and symptomatic anemia if they have sEPO levels below 500 IU/L.

The recommended sEPO level cutoff of 500 IU/L seems quite high, given that most studies and prediction scores use
cutoffs of 100 or 200 IU/L (Tables 1 and 2). Also, many kits used to assess sEPO levels have detection limits of 100 IU/L [29–32] or 200 IU/L [33]. Further, sEPO levels can vary depending on factors such as hemoglobin level, time since last transfusion, and time of day. Therefore, a level of 500 IU/L was likely chosen for the guidelines to avoid having to deny ESAs to patients who might still respond to them. Of course, rather than relying solely on an sEPO level below 500 IU/L, it may be beneficial to use one of the predictive scoring systems described in Table 2 to further ascertain the likelihood of response to ESAs.

Based on three large studies of mainly lower-risk MDS patients treated with ESAs with or without G-CSF, approximately 80% of patients have sEPO levels below 200 IU/L [47, 56] and only around 10% of patients have sEPO levels above 500 IU/L [46]. Therefore, approximately 90% of lower-risk MDS patients would be eligible to receive ESAs according to guidelines. Given that only around 10–20% of patients with sEPO levels above 500 IU/L would likely respond to ESAs [39, 40, 46], such patients are recommended to receive alternative treatments (e.g., biologic response modifiers or hypomethylating agents) [8]. It should be noted that patients with sEPO levels of 200–500 IU/L have a lower chance of response than those with sEPO levels below 200 IU/L (see Table 1) and are thus more likely to require additional/alternative treatments. In patients with no response to ESAs with or without G-CSF after 3 months (or if response is lost), alternative treatments (e.g., lenalidomide) are recommended [8].

### Additional prognostic uses of sEPO among patients with MDS

sEPO levels have not only been correlated with response to ESAs. Various studies have also examined whether sEPO levels affect duration of response [44, 47, 59] and overall survival [41, 49, 55] among patients treated with ESAs. Other studies have examined whether sEPO levels can affect response to non-ESA treatments [69–72], or the effect of sEPO on progression to AML and overall survival among patients with de novo MDS [73].

### Duration of response in patients treated with ESAs

Three studies were identified that reported duration of response to ESAs with or without G-CSF by sEPO level [44, 47, 59]. Stasi et al. [44] reported response durations by sEPO level among 24 responders to darbepoetin alpha. Although no statistical analyses were performed, there did appear to be some correlation between longer survival and lower sEPO. However, Kosmider et al. [59] reported that sEPO level was not significantly correlated with response duration among 79 patients.
patients treated with an ESA with or without G-CSF. Similarly, in a study of 403 patients who received EPO with or without G-CSF, Park et al. [47] found that there was no significant difference in duration of response using a cutoff of 200 IU/L (20 months among patients with sEPO levels below 200 IU/L; 25 months among those with sEPO levels ≥ 200 IU/L; HR, 1.0; 95% CI, 0.6–1.7; P = 0.97).

Overall survival in patients treated with ESAs

Various studies have reported on overall survival among patients treated with ESAs by sEPO level, but with inconsistent findings. In a study of 66 patients treated with EPO, Wallvik et al. [41] reported that median survival generally increased with decreasing sEPO level (e.g., 25 months for those with sEPO > 200 IU/L; 28 months for ≤ 200 IU/L; 38 months for ≤ 100 IU/L; and 65 months for ≤ 50 IU/mL). However, this was only significant for the 50, 70, and 100 IU/L cutoffs, but not for the 40, 150, or 200 IU/L cutoffs. Similarly, among 53 patients treated with EPO, survival was better among those with sEPO levels lower than 200 IU/L (34.2%) than those with 200 IU/L and higher (13.3%), after a median follow-up of 5.8 years [49]. In a study that categorized patients as relapsed after ESAs (n = 66) or refractory to ESAs (n = 120), survival decreased with lower sEPO, but only among those who responded and then relapsed (median survival 30.7 months [sEPO ≤ 100 IU/L] vs not reached [sEPO > 100 IU/L]; HR, 0.38; 95% CI, 0.15–0.94; P = 0.036) [55]. Among patients with refractory MDS, the difference was not significant (median survival 38.6 months [sEPO ≤ 100 IU/L] vs 50.8 months [sEPO > 100 IU/L]; HR, 0.88; 95% CI, 0.59–1.33; P = 0.56) [55]. The mechanism underlying the inverse relationship between sEPO and overall survival is not fully understood but may involve a combination of factors. Resistance to endogenous EPO, a predictor of poor outcome [55, 62], can result in elevated sEPO levels. High EPO level, therefore, could be a marker of more aggressive disease that defines a population of patients with poor prognosis.

Prediction of response to non-ESA treatments

To our knowledge, three studies have reported on erythroid response to lenalidomide with or without EPO in transfusion-dependent, ESA-refractory/ineligible patients with non-del(5q) lower-risk MDS (Table 3) [69–71]. Santini et al. [69] reported significantly better responses in patients with sEPO ≤ 500 IU/L versus > 500 IU/L by univariate analysis, but not by multivariate analysis. They also reported a significant trend for response by various cutoffs (Table 3). In a study by Toma et al. [70], an sEPO cutoff of 100 IU/L was predictive of response in univariate (OR, 3.3; 95% CI, 1.4–7.9; P = 0.009) and multivariate (OR, 4.1; 95%, CI 1.3–12.6; P = 0.02) analyses. In a smaller study, lower mean sEPO levels were reported among responders versus non-responders, but this was not significant [71].

Erythroid response in MDS patients receiving luspatercept has also been reported to vary by sEPO level (76% for sEPO < 200 IU/L; 58% for 200–500 IU/L; 43% for > 500 IU/L) [72]. Using a cutoff of 100 IU/L, sEPO had a significant effect on response in univariate and multivariate analyses (details in Table 3).

Prediction of progression to AML and overall survival in patients with de novo MDS

Cortesao et al. [73] examined the effect of sEPO level on progression to AML and overall survival in a study of 102 patients with de novo MDS. They found that patients who developed AML had higher mean sEPO levels than those who did not (P < 0.05) and that a sEPO level above 57 IU/L had an influence on progression. The authors also reported that overall survival increased with decreasing sEPO levels (P = 0.03).

A higher sEPO level is associated with a low probability of response to ESAs [47], and it has been suggested that failure of ESA therapy is a marker of poor prognosis in patients with lower-risk MDS [55, 62]. The relationship between response to ESAs and the incidence of AML has been evaluated in several studies. In a study involving 253 patients with non-del(5q) lower-risk MDS who failed ESA therapy, the 5-year cumulative incidence of AML was significantly higher in patients experiencing early ESA failure (i.e., relapse within 6 months of response) compared with patients experiencing later failure (21.6% vs 9%; P = 0.02) [55].

Similarly, in a study of 1698 patients with non-del(5q) lower-risk MDS, Park et al. [62] found that patients experiencing primary ESA failure had a higher risk of progression to AML than those experiencing secondary failure (i.e., relapse after an initial erythroid response; 16.7% vs 8.1%; P = 0.001).
### Table 3  
**sEPO levels predictive of erythroid response to treatments other than ESAs among patients with MDS**

| Reference   | Treatment; patients                                                                 | n   | Response definition                                                                 | sEPO responders vs non-responders, IU/L\(^a\) | sEPO cutoffs, IU/L | Erythroid response by sEPO, % |
|-------------|-------------------------------------------------------------------------------------|-----|-------------------------------------------------------------------------------------|-----------------------------------------------|-------------------|--------------------------------|
| Santini \[69\] | Lenalidomide; TD, ineligible/ refractory to ESAs, non-del(5q)                      | 160 | Transfusion independence for ≥ 8 weeks                                              | NR                                           | ≤ 500 vs > 500    | 34 vs 16 (\(P_{uni} = 0.015; P_{multi} = NS\)) |
|             |                                                                                     |     |                                                                                     | ≤ 100 vs 100–200 vs 200–500 vs > 500          | 43 vs 33 vs 23 vs 16 (\(P_{trend} = 0.002\)) |                  |
| Toma \[70\]  | Lenalidomide ± EPO; TD, ESA-refractory, non-del(5q)                                | 131 | IWG 2006\(^b\)                                                                      | NR                                           | < 100 vs ≥ 100    | 47 vs 21 (\(P_{uni} = 0.0087; P_{multi} = 0.016\)) |
| Komrokji \[71\] | Lenalidomide; TD, failed rhEPO, non-del(5q)                                        | 32  | IWG 2000\(^c\)                                                                      | 255 ± 283 vs 870 ± 1298 (\(P = NS\))         | NR                             | NR                             |
| Platzbecker \[72\] | Luspatercept; TD, mainly failed ESAs                                                | 58  | IWG 2006\(^b\)                                                                      | NR                                           | < 100 vs ≥ 100    | 76 vs 58 vs 43 (\(P = NS\)) |

\(EC_{uni}\) estimated coefficient by univariate analysis, \(EC_{multi}\) estimated coefficient by multivariate analysis, \(EPO\) erythropoietin, \(ESA\) erythropoiesis-stimulating agent, \(IWG\) International Working Group, \(MDS\) myelodysplastic syndromes, \(NR\) not reported, \(NS\) not significant, \(P_{multi}\) \(P\) value by multivariable analysis, \(P_{trend}\) \(P\) value for the trend, \(P_{uni}\) \(P\) value by univariate analysis, \(rhEPO\) recombinant human erythropoietin, \(SD\) standard deviation, \(sEPO\) serum erythropoietin, \(TD\) transfusion dependent

\(^a\) Values are mean ± SD for responders versus non-responders

\(^b\) IWG 2006 response criteria: for patients with pretreatment Hb < 110 g/L, ≥ 15 g/L increase in Hb; reduction of ≥ 4 RBC transfusions/8 weeks versus pretreatment 8 weeks (only RBC transfusions for a Hb ≤ 9.0 g/dL). Responses have to last ≥ 8 weeks [38]

\(^c\) IWG 2000 response criteria: for patients with pretreatment Hb < 110 g/L, ≥ 10 g/L increase in Hb; for RBC transfusion-dependent patients, 50% decrease in transfusion requirements. Responses have to last ≥ 2 months [39]
patients [35, 75], suggesting that patients with worse anemia (i.e., lower hemoglobin) may have higher levels of sEPO. Patients who are resistant to ESAs have higher sEPO and lower hemoglobin levels than those who respond (Tables 1 and 2), so these factors may be indicative of reduced bone marrow responsiveness.

Several mechanisms for ineffective hematopoiesis in patients with MDS have been discussed in the literature. Spinelli et al. [76] have reported that EPO signaling is affected in MDS patients. They found that EPO failed to activate extracellular signal-regulated kinase (ERK) 1/2 or STAT5 in 64% of cases in CD71 + CD45− cells from patients with MDS [76]. In the same study, in vivo ESA response correlated with in vitro EPO-dependent STAT5 activation in 91% of cases [76]. Frisan et al. [50] have reported that phospo (p)-ERK 1/2 expression—in both the steady state and after EPO stimulation—is defective in cultured MDS erythroblasts. However, Claessens et al. [77] have reported that EPO signaling pathways (STAT5, Akt, and ERK 1/2) are normally activated in MDS erythroid progenitors. Therefore, the role of EPO signaling in patients with MDS is unclear. Methodological differences, including the method used to measure EPO signaling pathway activity, may explain the discrepancy in findings between these studies.

Claessens et al. [77] have also reported that MDS erythroid progenitors have higher apoptosis rates than normal cells—which can be explained by the excess of Fas ligand during the differentiation stage of erythroid progenitors—and that patients with MDS produce less erythroid burst-forming units (BFU-E) than controls. Interestingly, Frisan et al. [50] have reported that responders to ESAs have significantly higher p-ERK 1/2 and BFU-E levels than non-responders (Fig. 1).

Reliable prognostic markers for response can be used to guide treatment options and, hence, improve outcomes. Despite limitations in its assessment, sEPO is an important predictor of response to ESAs with or without G-CSF in patients with lower-risk MDS. Lower sEPO levels (up to 500 IU/L) have thus been included in treatment algorithms for patients with lower-risk MDS to define whether ESAs are indicated [8, 68]. However, in clinical practice, a sEPO cutoff level of 200 IU/L is more likely to be indicative of response, and various scoring systems can be used to further enhance response prediction. For patients who do not respond to ESAs alone, G-CSF can be added; if they are refractory to this combination, other treatment options (e.g., lenalidomide) may be required [8]. Studies of other MDS therapies (e.g., lenalidomide, luspatercept) have also shown that patients with lower sEPO levels are more likely to have a hematologic response. Overall, there is a wealth of evidence that lower sEPO levels are predictive of hematologic response—particularly to ESAs. Further, clinical trials should use sEPO thresholds to ensure more homogeneous cohorts. Previous studies have shown that more than 97% of patients with MDS have sEPO levels < 500 IU/L [62]. Current European guidelines recommend erythropoietin-alpha for patients with sEPO levels < 200 IU/L [78], who represent approximately 86% of patients with MDS [56].

Acknowledgments The authors received editorial and writing support provided by Daniel Gilmartin, PhD, of Excerpta Medica, supported by Celgene Corporation. The authors are fully responsible for the content and editorial decisions for this manuscript.

Authors’ contributions All authors took part in the drafting of this review manuscript and revising it critically for important intellectual content. All authors read and approved the final manuscript.

Funding information This study was funded by the Celgene Corporation, Summit, NJ, USA.

Compliance with ethical standards

Conflict of interest S.P. received research support from Celgene Corporation, Janssen, Pfizer, and Roche. C.K., M.M., N.C., and A.T.G. declare that they have no competing interests. U.P. received research support from Amgen and Janssen.

Ethical approval This article does not contain any studies with human participants or animals performed by any of the authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Li J (2013) Myelodysplastic syndrome hematopoietic stem cell. (2013). Int J Cancer 133:525–533
2. Zini G (2017) Diagnostics and prognostication of myelodysplastic syndromes. Ann Lab Med 37:465–474
3. Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292–2302
4. Arber DA, Onazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405
5. Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088
6. Malcovati L, Géring U, Kuendgen A, Della Porta MG, Paccuttio C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503–3510
7. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H,
22. Broudy VC, Malcovati L, Cazzola M, Cermak J, Fontans C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstocker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valient P, Vallespi T, van de Loosdrecht AA, Garming U, Haase D (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454–2465

8. Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Franklin O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komorjki R, Kujawski LA, Maness LJ, O’Donnell MR, Pollyea DA, Shami PJ, Stein BL, Walker AR, Westervelt P, Zeidman A, Shead DA, Smith C (2019) Myelodysplastic syndromes; referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myelodysplastic Syndromes V2.2019 © National Comprehensive Cancer Network, Inc, 2019. All rights reserved. Accessed May 8, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

9. Carnot MP, Deflandre C (1906a) Sur l’activité hémopoïétique des différents organes au cours de la régénération du sang. C R Acad Sci Paris 143:432–435

10. Carnot P, Deflandre C (1906b) Sur l’activité hémopoïétique du sérum au cours de la régénération du sang. C R Acad Sci Paris 143:384–386

11. Bonnorf F, Jalavisto E (1948) A humoral mechanism in anoxic erythropoiesis. Acta Physiol Scand 16:150–170

12. Jelkmann W (2007) Erythropoietin after a century of research: younger than ever. Eur J Haematol 78:183–205

13. Jacobson LO, Goldwasser E, Fried W, Jacobson LO, Bethard WF (1955) Recombinant DNA-derived Erythropoietin: collaborative study of four recombinant DNA-derived erythropoietins and two highly purified human urinary erythropoietins. J Endocrinol 134:459–484

14. Garcia JF, Sherwood J, Goldwasser E (1979) Radioimmunoassay of erythropoietin. Blood Cells 5:405–419

15. Lacombe C, Da Silva JL, Bruneval P, Salzmann JL, Casadevall N, Mufson A, Seehra J, Jones SS, Hewick R, Fritsch EF, Kawakita M, Shimizu T, Miyake T (1985) Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 313:860–861

16. Fried W (1972) The liver as a source of extrarenal erythropoietin production. Blood 40:671–677

17. Miyake T, Kung CK, Goldwasser E (1977) Purification of human erythropoietin. J Biol Chem 252:5558–5564

18. Jacobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Muñson A, Seehra J, Jones SS, Hewick R, Fritsch EF, Kawakita M, Shimizu T, Miyake T (1985) Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 313:860–861

19. Egrie JC, Strickland TW, Lane J, Aoki K, Cohen AM, Smalling R, Trail G, Lin FK, Browne JK, Hines DK (1986) Characterization and biological effects of recombinant human erythropoietin. Immunobiology 172:213–224

20. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z (1985) Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 82:7580–7584

21. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. New Eng J Med 316:73–78

22. Broudy VC, Lin N, Brice M, Nakamoto B, Papayannopoulou T (1991) Erythropoietin receptor characteristics on primary human erythroid cells. Blood 77:2583–2590

23. Watowich SS (2011) The erythropoietin receptor: molecular structure and hematopoietic signaling pathways. J Invest Med 59:1067–1072

24. Plzak LF, Fried W, Jacobson LO, Bethard WF (1955) Demonstration of stimulation of erythropoiesis by plasma from anemic rats using Fes59. J Lab Clin Med 46:671–678

25. Cotes PM, Bangham DR (1966) The international reference preparation of erythropoietin. Bull World Health Organ 35:751–760

26. Annable L, Cotes PM, Mussett MV (1972) The second international reference preparation of erythropoietin, human, urinary, for bioassay. Bull World Health Organ 47:99–112

27. Störing PL, Gaines Das RE (1992) The International Standard for Recombinant DNA-derived Erythropoietin: collaborative study of reference preparations of DNA-derived erythropoietins and two highly purified human urinary erythropoietins. J Endocrinol 134:459–484

28. Garcia JF, Sherwood J, Goldwasser E (1979) Radioimmunoassay of erythropoietin. Blood Cells 5:405–419

29. abcam. Human Erythropoietin ELISA Kit. https://www.abcam.com/human-erythropoietin-elsa-kit-epo.ab119522.html. Accessed 15 March 2018.

30. BioVendor. Erythropoietin Human ELISA. https://www.biovendor.com/erythropoietin-human-elsa. Accessed 15 March 2018.

31. Stemcell Technologies. Erythropoietin (EPO) ELISA Kit. https://www.stemcell.com/erythropoietin-eipo-elsa-kit.html. Accessed 15 March 2018.

32. ThermoFisher. Epo Human ELISA Kit, Short incubation. https://www.thermofisher.com/order/catalog/product/BMS2035. Accessed 15 March 2018.

33. R&D Systems. Human Erythropoietin Quantikine IVD ELISA Kit. https://www.rndsystems.com/products/human-erythropoietin-quantikine-ivd-elsa-kit_de00. Accessed 15 March 2018.

34. Grote Beverborg N, Verweij N, Klip IT, van der Wal HH, Voors AA, van Veldhuisen DJ, Gansevoort RT, Bakker SJ, van der Harst P, Pl v d M (2015) Erythropoietin in the general population: reference ranges and clinical, biochemical and genetic correlates. PLoS One 10:e0125215

35. Nakazaki K, Nannya Y, Kurokawa M (2014) Distribution of serum erythropoietin levels in lower risk myelodysplastic syndrome cases. Int J Hematol 99:53–56

36. Pasqualetti P, Collacciani A, Casale R (2000) Circadian rhythm of serum erythropoietin in myelodysplastic syndromes. Eur Rev Med Pharmacol Sci 4:111–115

37. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Löwenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671–3674

38. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419–425

39. Hellstrom-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J, Ost A, Greenberg P (1997) Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 99:344–351

40. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneus J, Dahl JM, Dybedal I, Grimfors G, Kanter-Lewensohn L, Linder O, Luthman M, Lööfberg E, Nilsson-Ehle H, Samuelsson J, Tangen JM, Winqvist I, Oberg G, Osterborg A, Ost A (1998) Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus
erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92:68–75

41. Wallvik J, Stenke L, Berntell P, Nordahl G, Hippe E, Harst R (2002) Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. Eur J Haematol 68:180–185

42. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, Grimfors G, Hesse-Sundin E, Jhorth M, Kanter-Lewensohn L, Linder O, Luthman M, Löfvenberg E, Oberg G, Porwit-MacDonald A, Räldt A, Samuelsson J, Tangen JM, Winquist I, Wisloff F (2003) A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120:1037–1046

43. Musto P, Lanza F, Balleeri E, Grossi A, Falcione A, Sanpaolo G, Bodenizza C, Scalzulli PR, La Sala A, Campioni D, Ghio R, Cascavilla N, Carella AM (2005) Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 128:204–209

44. Stasi R, Abbruzzese E, Lanzetta G, Terzoli E, Amadori S (2005) Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 16:1921–1927

45. Mannone L, Gardin C, Quarrè MC, Bernard JF, Vassilieff D, Ades L, Park S, Vaultier S, Hamza F, Beyne-rauzy MO, Cheze S, Giraudier S, Agape P, Legros L, Violett L, Dreyfus F, Fenaux P (2006) High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 133:513–519

46. Gabrilove J, Paquette R, Lyons RM, Mushita C, Sekeres MA, Tomita D, Dreiling L (2008) Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 142:379–393

47. Park S, Grabar S, Kelaidi C, Beyne-rauzy O, Picard F, Bardet V, Coiteux V, Leroux G, Lepelley P, Daniel MT, Cheze S, Mahé B, Ferrant A, Ravoet C, Escoffre-Barbe M, Adès L, Vey N, Aljassem L, Stamatoullas A, Mannone L, Dombret H, Bourgeois K, Greenberg P, Fenaux P, Dreyfus F (2008) Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 111:574–582

48. Gotlib J, Lavori P, Quesada S, Stein RS, Shahnia S, Greenberg PL (2010) A phase II intrapatient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte colony stimulating factor in myelodysplastic syndromes. Am J Hematol 84:15–20

49. Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, Paietta E, van der Jagt R, Houston J, Thomas ML, Cella D, Rowe JM (2009) Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 114:2393–2400

50. Frisan E, Pawlikowska P, Pierre-Eugene C, Viallon V, Gibault L, Park S, Mayeux P, Dreyfus F, Porteu P, Fontenay M (2010) p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes. Haematologica 95:1964–1968

51. Westers TM, Alhan C, Chamuleau ME, van der Vorst MJ, Eeltink C, Ossenkoppelle GJ, van de Loosdrecht A (2010) Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood 115:1779–1784

52. Park S, Kelaidi C, Sapena R, Vassilieff D, Beyne-rauzy O, Coiteux V, Vey N, Ravoet C, Cheze S, Rose C, Legros L, Stamatoullas A, Escoffre-Barbe M, Guerci A, Chaury MP, Fenaux P, Dreyfus F (2010) Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients. Leuk Res 34:1430–1436

53. Villegas A, Arrizabalaga B, Fernandez-Lago C, Castro M, Mayans JR, Gonzalez-Porras JR, Duarte RF, Remacha AF, Luño E, Gasquet J (2011) Darbepoetin alfa for anaemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response. Curr Med Res Opin 27:951–960

54. Kelaidi C, Beyne-Rauzy O, Braun T, Sapena R, Cougoul P, Adès L, Pillard F, Lomberto C, Czarniot JC, Guerci A, Choufi B, Stamatoullas A, Slama B, De Renzis B, Ame S, Damaj G, Boyer F, Chaury MP, Legros L, Cheze S, Testu A, Gyan E, Bénê MC, Rose C, Dreyfus F, Fenaux P (2013a) High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol 92:621–631

55. Kelaidi C, Park S, Sapena R, Beyne-Rauzy O, Coiteux V, Vey N, Stamatoullas A, Choufi F, Delaunay J, Gourin MP, Cheze S, Ravoet C, Ferrant A, Escoffre-Barbe M, Aljassem L, Raffoux E, Itzykson R, Adès L, Dreyfus F, Fenaux P (2013b) Long-term outcome of anaemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. Leukemia 27:1283–1290

56. Santini V, Schemenau J, Levis A, Balleeri E, Sapena R, Adès L, Guerci A, Beyne-Rauzy O, Gourin MP, Cheze S, Stamatoullas A, Sanna A, Gioia D, Cametti G, Ferrero D, Raffoux E, Rose C, Poloni A, Prebet T, Legros L, Natarajan-Amé S, Fenaux P, Germing U, Dreyfus F, Park S (2013) Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? Blood 122:2286–2288

57. Molteni A, Riva M, Greco R, Nichelatti M, Ravano E, Marbello L, Nosari A, Morra E (2013) Verifying Hellstrom-Lindberg score as predictive tool for response to erythropoietin therapy according to the “International Working Group” criteria, in anemic patients affected by myelodysplastic syndrome: a monocentric experience. Int J Hematol 97:472–479

58. Jang JH, Harada H, Shibayama H, Shimazaki R, Kim HJ, Sawada K, Mitani K (2015) A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. Int J Hematol 102:401–412

59. Kosmider O, Fasset P, Santini V, Platzbecker U, Andrieu V, Zini G, Beyne-Rauzy O, Guerci A, Masala E, Balleeri E, Bulycheva E, Dreyfus F, Fenaux P, Fontenay M, Park S (2016) Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes? Haematologica 2016(101):e280–e283

60. Buckstein R, Balleeri E, Wells R, Santini V, Sanna A, Salvetti C, Crisa E, Allione B, Danise P, Finelli C, Clavio M, Poloni A, Salvi F, Cilloni D, Oliva EN, Musto P, Houston B, Zhu N, Geddes M, Leitch H, Leber B, Sabloff M, Nevill TJ, Yee KW, Storring JM, Francis J, Maurillo L, Latagliata R, Spiriti MAA, Andriani A, Piccioni AL, Fianchi L, Fenu S, Gumenyuk S, Buckssiano F (2017) ITACA: a new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems. Ann Hematol 92:1037–1046

61. Houston BL, Jayakar J, Wells RA, Lenis M, Zhang L, Zhu N, Leitch HA, Nevill TJ, Yee KW, Leber B, Sabloff M, St-Hilaire E, Kumar R, Geddes M, Shamy A, Storring JM, Keating MM, Eley M, Delage R, Mamedov A, Buckstein R (2017) A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry. Ann Hematol 96:2025–2029
70. Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P (2017) Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents. J Clin Oncol 35:1591–1597

69. Remacha AF, Arrizabala B, Villegas A, Manteiga R, Calvo T, Julia A, Fernández Fuertes I, González FA, Font L, Juncá J, del Arco A, Malcorra JJ, Equiza EP, de Mendigüen BP, Romero M (1999) Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of respondents. The Spanish Erythropathy Group. Haematologica 84:1058–1064

68. Park S, Fenaux P, Greenberg P, Mehta B, Callaghan F, Kim C, Stasi R, Brunetti M, Bussa S, Conforti M, Martin LS, La Presa M, Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Remacha AF, Arrizabala B, Villegas A, Manteiga R, Calvo T, Julia A, Fernández Fuertes I, González FA, Font L, Juncá J, del Arco A, Malcorra JJ, Equiza EP, de Mendigüen BP, Romero M (1999) Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of respondents. The Spanish Erythropathy Group. Haematologica 84:1058–1064

67. Gerds AT, Sekeres MA (2014) Initial transfusion frequency and meta-analysis. Br J Haematol 174:730–747

66. Park S, Fenaux P, Greenberg P, Mehta B, Callaghan F, Kim C, Tomita D, Xu H (2016) Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis. Br J Haematol 174:730–747

65. Stasi R, Brunetti M, Bussa S, Conforti M, Martin LS, La Presa M, Bianchi M, Parma A, Pagano A (1997) Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin outside the setting of uremia. Blood 89:4248–4267

64. Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellstrom-Lindberg E (2004) The WHO classification of MDS does make a difference. Blood 103:3265–3270

63. Stasi R, Brunetti M, Bussa S, Conforti M, Martin LS, La Presa M, Bianchi M, Parma A, Pagano A (1997) Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome. Clin Lab Haematol 19:197–201

62. Park S, Fenaux P, Greenberg P, Mehta B, Callaghan F, Kim C, Tomita D, Xu H (2016) Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis. Br J Haematol 174:730–747

61. Gerds AT, Sekeres MA (2014) Initial transfusion frequency and survival in myelodysplastic syndromes: hopping onto a fast train to nowhere. Leuk Lymphoma 55:2221–2222

60. Santini V (2016) Treatment of lower-risk myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2016:462–469

59. Santini V, Almeida A, Giagounidis A, Gropper S, Jonasova A, Vey N, Mufti GJ, Buckstein R, Mittelman M, Platzbecker U, Shpilberg O, Radsak M, Wolf F, Zang X, Laadem A, Sherman ML, Attie KM, Giagounidis A (2017) Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicenter, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol 18:1338–1347

58. Cortesao E, Tenreiro R, Ramos S, Pereira M, Cesar P, Carda JP, Gomes M, Rito L, Magalhães E, Gonçalves AC, Silva NC, Geraldes C, Pereira A, Ribeiro L, Nascimento Costa JM, Ribeiro AB (2015) Serum erythropoietin as prognostic marker in myelodysplastic syndromes. Acta Med Port 28:720–725

57. Cazzola M, Mercuriali F, Brugnara C (1997) Use of recombinant human erythropoietin in patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents. J Clin Oncol 35:1591–1597

56. Remacha AF, Arrizabala B, Villegas A, Manteiga R, Calvo T, Julia A, Fernández Fuertes I, González FA, Font L, Juncá J, del Arco A, Malcorra JJ, Equiza EP, de Mendigüen BP, Romero M (1999) Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of respondents. The Spanish Erythropathy Group. Haematologica 84:1058–1064

55. Suzuki T, Oh I, Ohmine K, Meguro A, Mori M, Fujiwara S, Yamamoto C, Nagai T, Ozawa K (2015) Distribution of serum erythropoietin levels in Japanese patients with myelodysplastic syndromes. Int J Hematol 101:32–36

54. Spinelli E, Caporale R, Buchi F, Masala E, Gozzini A, Sanna A, Sassolini F, Valencia A, Bosi A, Santini V (2012) Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients. Clin Can Res 18:3079–3089

53. Claessens YE, Bousscar D, Dunport JM, Picard F, Melle J, Gisselbrecht S, Lacombe C, Dreyfus F, Mayeux P, Fontenay-Roupie M (2002) In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 99:1594–1601

52. Malcovati L, Hellström-Lindberg E, Bowen D, Adès L, Cermak J, del Cañizo C, Della Porta MG, Fenaux P, Gattermann N, Germing U, Jansen JH, Mittelman M, Mufti G, Platzbecker U, Sanz GF, Selleslag D, Skov-Holm M, Stauder R, Symeonidis A, van de Loosdrecht AA, de Witte T, Cazzola M (2013) Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122:2943–2964

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.